DRG Market Assessment reports

Acute myeloid leukemia (AML), the most common form of leukemia in adults, has historically been associated with poor five-year overall survival rates. AML is witnessing a paradigm shift from…

The type 2 diabetes therapy market will steadily expand over the 2019-2029 study period, fueled by increasing prevalence and high unmet need for drugs that can effectively control the disease in…

Epilepsy, which afflicts approximately 4.7 million people in the major markets according to DRG epidemiology, is a heterogeneous condition requiring individualized treatment based largely on a…

MARKET OUTLOOK Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin; it typically develops in early childhood and can persist into…

Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin, which typically develops in early childhood and can persist into adulthood. The…

The incidence of gastroesophageal cancer—encompassing gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ) adenocarcinoma—continues to rise; however, treatment options remain…

The biosimilar / follow-on insulin sector of the diabetes therapy market is evolving. Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine…

Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness. The key treatment goals…

The Alzheimer’s disease (AD) market comprises a handful of symptomatic options that offer modest efficacy for a limited duration, leaving wide open the opportunity for more-effective alternatives…

DRG Epidemiology’s coverage of pemphigus vulgaris comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany,…

The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s Spiriva),…

Dravet syndrome (DS) is a rare, severe, pediatric-onset form of epilepsy characterized by developmental delay or regression and multiple types of difficult-to-treat seizures. Only a handful of…